Affordable Access

deepdyve-link
Publisher Website

Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-Up.

Authors
  • Tardivon, Coralie1
  • Desmée, Solène2
  • Kerioui, Marion1, 2
  • Bruno, René3
  • Wu, Benjamin4
  • Mentré, France1
  • Mercier, François5
  • Guedj, Jérémie1
  • 1 Université de Paris, IAME, INSERM, F-75018 Paris, France. , (France)
  • 2 UMR 1246, Université de Tours, Université de Nantes, Inserm SPHERE, Tours, France. , (France)
  • 3 Clinical Pharmacology, Roche/Genentech, Marseille, France. , (France)
  • 4 Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA.
  • 5 Clinical Pharmacology, Roche Innovation Center, Basel, Switzerland. , (Switzerland)
Type
Published Article
Journal
Clinical Pharmacology & Therapeutics
Publisher
Wiley (Blackwell Publishing)
Publication Date
Oct 01, 2019
Volume
106
Issue
4
Pages
810–820
Identifiers
DOI: 10.1002/cpt.1450
PMID: 30985002
Source
Medline
Language
English
License
Unknown

Abstract

We characterized the association between tumor size kinetics and survival in patients with advanced urothelial carcinoma treated with atezolizumab (anti-programmed death-ligand 1, Tecentriq) using a joint model. The model, developed on data from 309 patients of a phase II clinical trial, identified the time-to-tumor growth and the instantaneous changes in tumor size as the best on-treatment predictors of survival. On the validation dataset containing data from 457 patients from a phase III study, the model predicted individual survival probability using 3-month or 6-month tumor size follow-up data with an area under the receptor-occupancy curve between 0.75 and 0.84, as compared with values comprised between 0.62 and 0.75 when the model included only information available at treatment initiation. Including tumor size kinetics in a relevant statistical framework improves the prediction of survival probability during immunotherapy treatment and may be useful to identify most-at-risk patients in "real-time." © 2019 Inserm. Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics.

Report this publication

Statistics

Seen <100 times